Firas El Chaer, MD
Hematology · Miami, FLNPI 1659624856
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (50.9%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 22 manufacturers reported payments, led by Syndax Pharmaceuticals, Inc. at 33.0% of the total. 2025 is the largest year on record at $89,406, more than ten times the $222 reported in 2019. Among hematology clinicians in FL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 101 payments — averaging $1037.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Syndax Pharmaceuticals, Inc.$35K
- Pharmaessentia USA Corporation$25K
- Sumitomo Pharma America, Inc.$12K
- Amgen$8K
- AbbVie$6K
- GSK$5K
- plus $15K from 16 others
Across 557 payments — averaging $2772.16 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pharmaessentia USA Corporation$999K
- Sumitomo Pharma America, Inc.$297K
- Bristol Myers Squibb$125K
- Sanofi$54K
- AbbVie$46K
- E.r. Squibb & Sons, L.L.C.$24K
What the payments were for
- Consulting fees$53,34051%
- Speaking & faculty fees$28,35027%
- Travel & lodging$10,62110%
- Food & beverage$3,5213%
- Education$8,9559%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Syndax Pharmaceuticals, Inc. | 26 | $34,608 |
| Pharmaessentia USA Corporation | 10 | $24,507 |
| Sumitomo Pharma America, Inc. | 10 | $11,923 |
| Amgen | 12 | $7,993 |
| AbbVie | 12 | $6,217 |
| GSK | 1 | $4,750 |
| Novartis | 4 | $3,089 |
| Taiho Oncology, Inc. | 2 | $2,607 |
| Morphosys, US Inc. | 4 | $2,598 |
| Merck | 1 | $2,240 |
| CTI Biopharma Corp. | 1 | $1,725 |
| Bristol Myers Squibb | 5 | $1,046 |
| Daiichi Sankyo Inc. | 1 | $650 |
| Sanofi | 2 | $141 |
| Pfizer | 1 | $127 |
| Sobi, Inc | 1 | $120 |
| Exelixis Inc. | 1 | $112 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $110 |
| Sanofi US Services Inc. | 1 | $83 |
| Geron Corporation | 2 | $70 |
| E.r. Squibb & Sons, L.L.C. | 2 | $44 |
| Janssen Scientific Affairs, LLC | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$104,787 in reported general payments places this provider in the 90th percentile of 79 hematology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OjjaaraMomelotinib Dihydrochloride | 31 | $823,028 |
| BesremiRopeginterferon Alfa-2b-Njft | 30 | $362,220 |
| InrebicFedratinib Dihydrochloride | 13 | $345,109 |
| JakafiRuxolitinib Phosphate | 20 | $284,518 |
| SprycelDasatinib | 22 | $246,288 |
| Lenalidomide | 17 | $228,392 |
| BosulifBosutinib | 12 | $164,900 |
| VenclextaVenetoclax | 53 | $99,219 |
| Imatinib Mesylate | 20 | $30,042 |
| Posaconazole | 18 | $15,996 |
| Acyclovir | 53 | $596 |
| Ciprofloxacin Hcl | 12 | $445 |
| Ondansetron Hcl | 14 | $234 |
| Allopurinol | 16 | $94 |
| Famotidine | 15 | $89 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKOjjaara | $4,750 | $823,02831 claims |
| Pharmaessentia USA CorporationBesremi | $24,507 | $362,22030 claims |
| Bristol Myers SquibbInrebic | $1,046 | $345,10913 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $44 | $246,28822 claims |
| PfizerBosulif | $127 | $164,90012 claims |
| AbbVieVenclexta | $6,217 | $99,21953 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 79 hematology providers in Florida.
Other hematology in Miami
- Terrence BradleyMiami$53K
- Jay SpiegelMiami$19K
- Jaime Roman DiazMiami$4K
- Offiong IkpattMiami$1K
- Lawrence SnetmanMiami$648
- Sharhabil AmmusMiami$446
- Jennifer Chapman-FredricksMiami$303
- Javier Pinilla-IbarzTampa$1.6M
- Rami KomrokjiTampa$855K
- Ahmed ZakariAltamonte Springs$383K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.